Pricing
  1. JP-listed companies
  2. ReproCELL Incorporated
  3. Financials
  4. Total non-current assets

ReproCELL Incorporated【JP:4978】

Market cap
¥16B
P/E ratio
-27.8x
Reprocell develops iPS cell technology for research and medical applications, providing lab products and services to pharmaceutical companies while advancing regenerative medicine treatments.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal non-current assets (Million JPY)YoY (%)
Mar 31, 20254,774+188.78%
Mar 31, 20241,653+40.90%
Mar 31, 20231,173-56.80%
Mar 31, 20222,716+238.43%
Mar 31, 2021803-2.38%
Mar 31, 2020822-36.16%
Mar 31, 20191,288+108.40%
Mar 31, 2018618-68.20%
Mar 31, 20171,943-7.75%
Mar 31, 20162,107-5.73%
Mar 31, 20152,235

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)